Research progress on immunotherapy of nasopharyngeal carcinoma / 中国肿瘤临床

Nasopharyngeal cancer (NPC) is an Epstein–Barr virus-associated malignant tumor. Radiation alone or concurrent chemo-radiotherapy is the principal treatment method and can generally achieve excellent efficacy for NPC patients. However, the prognosis of locoregionally advanced disease or distant metastasis remains poor. Currently, immunotherapy has become a new treatment of sol-id tumors, and it is mainly activating the antitumor immune system of the body. The review aims to explore the progress of immuno-therapy, including adoptive immunotherapy, tumor vaccines, and immune checkpoint inhibitors in NPC treatment.